LeonaBio (LONA) Long-Term Deferred Tax (2022 - 2023)
LeonaBio (LONA) reported Long-Term Deferred Tax of $25.2 million for Q4 2023, up 135.51% year-over-year from $10.7 million in Q4 2022, and up 135.51% quarter-over-quarter from $10.7 million in Q4 2022.
LeonaBio (LONA) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
LeonaBio (LONA) has 2 years of Long-Term Deferred Tax data on file, last reported at $25.2 million in Q4 2023.
- Long-Term Deferred Tax for Q4 2023 came in at $25.2 million, up 135.51% year-over-year; the trailing twelve-month figure through Dec 2023 was $25.2 million (up 135.51% YoY), and the FY2023 annual result was $25.2 million, up 135.51% from the prior year.
- Long-Term Deferred Tax advanced to $25.2 million in Q4 2023 per LONA's latest filing, from $10.7 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $25.2 million in Q4 2023 and troughed at $10.7 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | LeonaBio | 154.12 Mn | 86.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 25.20 Mn |
| Dec 31, 2022 | 10.70 Mn |